Table 3.
Specific antibody responses to the receptor binding domain, and neutralising antibodies to live SARS-CoV-2
|
Day 14 |
Day 28 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Low dose group (n=36) | Middle dose group (n=36) | High dose group (n=36) | p value | Low dose group (n=36) | Middle dose group (n=36) | High dose group (n=36) | p value | |
| ELISA antibodies to the receptor binding domain | ||||||||
| GMT | 76·5 (44·3–132·0) | 91·2 (55·9–148·7) | 132·6 (80·7–218·0) | 0·29 | 615·8 (405·4–935·5) | 806·0 (528·2–1229·9) | 1445·8 (935·5–2234·5) | 0·016 |
| ≥4-fold increase | 16 (44%) | 18 (50%) | 22 (61%) | 0·35 | 35 (97%) | 34 (94%) | 36 (100%) | 0·77 |
| Neutralising antibodies to live SARS-CoV-2 | ||||||||
| GMT | 8·2 (5·8–11·5) | 9·6 (6·6–14·1) | 12·7 (8·5–19·0) | 0·24 | 14·5 (9·6–21·8) | 16·2 (10·4–25·2) | 34·0 (22·6–50·1) | 0·0082 |
| ≥4-fold increase | 10 (28%) | 11 (31%) | 15 (42%) | 0·42 | 18 (50%) | 18 (50%) | 27 (75%) | 0·046 |
Data are mean (95% CI) or n (%). The p values are the result of comparison across the three dose groups. If the difference was significant across the three groups, the differences between groups were estimated with 95% CIs. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. GMT=geometric mean titre.